Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adagio Medical Holdings (ADGM) Other Non-Current Liabilities (2023 - 2026)

Adagio Medical Holdings has reported Other Non-Current Liabilities over the past 4 years, most recently at $263000.0 for Q1 2026.

  • Quarterly Other Non-Current Liabilities fell 92.73% to $263000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $263000.0 through Mar 2026, down 92.73% year-over-year, with the annual reading at $132000.0 for FY2025, 96.35% down from the prior year.
  • Other Non-Current Liabilities was $263000.0 for Q1 2026 at Adagio Medical Holdings, up from $132000.0 in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $3.6 million in Q4 2024 and troughed at $8000.0 in Q4 2023.
  • The 4-year median for Other Non-Current Liabilities is $374500.0 (2025), against an average of $1.4 million.
  • Year-over-year, Other Non-Current Liabilities surged 45100.0% in 2024 and then tumbled 96.35% in 2025.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $8000.0 in 2023, then surged by 45100.0% to $3.6 million in 2024, then tumbled by 96.35% to $132000.0 in 2025, then soared by 99.24% to $263000.0 in 2026.
  • Per Business Quant, the three most recent readings for ADGM's Other Non-Current Liabilities are $263000.0 (Q1 2026), $132000.0 (Q4 2025), and $486000.0 (Q3 2025).